Cyclovirobuxin D
|
|
Cyclovirobuxin D 속성
- 녹는점
- 220-221 °C (decomp)(Solv: acetone (67-64-1))
- 끓는 점
- 524.75°C (rough estimate)
- 밀도
- 0.9815 (rough estimate)
- 굴절률
- 1.5300 (estimate)
- 저장 조건
- Store at -20°C
- 용해도
- Soluble to 20 mg/mL (49.66 mM) in Ethanol
- 물리적 상태
- cryst.
- 산도 계수 (pKa)
- 15.12±0.70(Predicted)
- 색상
- 하얀색
- LogP
- 4.635 (est)
- CAS 데이터베이스
- 860-79-7(CAS DataBase Reference)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
안전지침서 | 24/25 | ||
---|---|---|---|
HS 번호 | 29420000 | ||
독성 | LD50 oral in mouse: 293mg/kg |
Cyclovirobuxin D C화학적 특성, 용도, 생산
개요
A Buxus alkaloid of the steroidal class, this base has been found in the strong base fraction of the alkaloidal extract from Buxus microphylla Sieb. et Zucco var. suffruticosa and B. microphylla Sieb. et Zucco var. suffruticosa Makino forma major. It is dextrorotatory having a specific rotation of [α]23D + 98° (c 4.40,CHC13)and yields a series of salts and derivatives including the dihydrobromide, m.p. 288-292°C (dec.); dihydriodide, m.p. 276-8°C (dec.); diperchlorate, m.p. 244- 5°C (dec.); dioxalate as an amorphous powder, m.p. 264-7°C (dec.): the N:Ndiacetyl derivative, m.p. 278-281°C (dec.) with [α]24D + 10° (c 1.94, CHC13) and the O,N,N-triacetyl derivative, m.p. 246-8°C with [α]24D - 12° (c 2.40, CHCI3)·The structure and stereochemistry of the base have been elucidated from chemical analysis, spectroscopic evidence and comparison with other alkaloids of this class.
물리적 성질
Appearance: colorless needle crystals. Solubility: sparingly soluble in acetone; slightly soluble in water; freely soluble in chloroform; soluble in methanol and ethanol. Melting point: 219–222?°C.역사
Cyclovirobuxine in the treatment of coronary heart disease began in 1969 . The medical teams of Chinese People’s Liberation Army No.86489 explored a treatment of coronary heart disease named Guo, prescription composed of Buxus microphylla (huangyangmu), Salvia miltiorrhiza Bge. (danshen), Ligustici Chuanxiong Rhizoma (chuanxiong), Belamcandae Rhizoma (shegan), Radix Aristolochiae (qingmuxiang) and Asari Radix et Rhizoma (xixin).In 1978, the Anhui Huangyang Research Cooperation Group carried out systematic experiments to determine the chemical structure and the separation and identification method of cyclovirobuxine by melting point determination, thin-layer chromatography, infrared spectroscopy, mass spectrometry and NMR . Three studies containing more than 300 cases of coronary heart disease patients treated with cyclovirobuxine showed that this drug can significantly improve angina, chest tightness, arrhythmia and other symptoms caused by coronary heart disease.
용도
Cyclovirobuxine D is a potential preventative agent of cardiac dysfunction.Indications
It is mainly used for the treatment of cardiovascular and cerebrovascular diseases in China, such as the coronary heart disease, arrhythmia, cerebral arteriosclerosis, cerebral embolism and brain vascular accident which are caused by insufficiency of cerebral blood supply.Pharmacology
Pharmacological studies have shown that cyclovirobuxine has a positive inotropic effect on the heart that may predominantly be due to the inhibition of cardiomyocyte membrane Na+-K+-ATPase activity and promotion of myocardial extracellular Ca2+ influx and cardiomyocyte Ca2+ release. Moreover, cyclovirobuxine could markedly reduce myocardial oxygen consumption and increase coronary blood flow, suggesting that it has definite anti-myocardial ischemia effect. Experiments also showed that cyclovirobuxine could induce marked inhibition of myocardial ischemia infarction and enhancement of anoxia tolerance in mice .Besides, cyclovirobuxine could have protective effect on the acute experimental cerebral ischemia in mice by bilateral ligation of common carotid arteries, prolong the life span of mice, increase blood flow and decrease the formation of thrombus during cerebral ischemia . In vitro experiments have also shown that cyclovirobuxine has neuroprotective effects on neurons and restrains PC12 cells from excitatory amino acid-induced injury .
Clinical Use
After decades of clinical observation, cyclovirobuxine has the therapeutic role of anti-myocardial ischemia and antiarrhythmia and protects against acute cerebral ischemia. In addition, cyclovirobuxine can cross the blood-brain barrier and improve brain microcirculation and oxygen supply to treat cerebral arteriosclerosis insufficiency.참고 문헌
Nakano, Terao, Tetrahedron Lett., 1035, 1045, (1964)Brown, Kupchan, J. Amer. Chem. Soc., 86, 4414, 4424 (1964)
Nakano, Terao,J. Chem. Soc., 4512, 4537 (1965)
Nakano, Hasegawa, ibid, 6688 (1965)
Cyclovirobuxin D 준비 용품 및 원자재
원자재
준비 용품
Cyclovirobuxin D 공급 업체
글로벌( 211)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Shanghai Zheyan Biotech Co., Ltd. | 18017610038 |
zheyansh@163.com | CHINA | 3620 | 58 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29888 | 58 |
Chengdu Biopurify Phytochemicals Ltd. | +8618080483897 |
sales@biopurify.com | China | 3772 | 58 |
Nanjing Dolon Biotechnology Co.,Ltd. | 18905173768 |
sales@dolonchem.com | CHINA | 2972 | 58 |
Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28180 | 58 |
Shaanxi Pioneer Biotech Co., Ltd . | +8613259417953 |
sales@pioneerbiotech.com | China | 3000 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 |
sales@chemdad.com | China | 39916 | 58 |
Shanghai Standard Technology Co., Ltd. | 18502101150 |
ft-sales@nature-standard.com | CHINA | 1923 | 58 |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 |
sales@conier.com | China | 49392 | 58 |
Cyclovirobuxin D 관련 검색:
Pachymic acid
ALLEOSIDE A
Poricoic acid A(F)
Carboxyatractyloside
Terrestrosin D
roburic acid
Terrestrosin K
Madecassoside
Madecassic acid
dipotassium dihydrogen 15alpha-hydroxy-2beta-[[2-O-isovaleryl-3,4-di-O-sulphonato-beta-D-glucopyranosyl]oxy]kaur-16-ene-18,19-dioate
Evodiamine
Tiapride
N-cyclodecylmethylamine
N,N''-DIMETHYL-1,12-DIAMINODODECANE
CYCLOVIROBUXINE:9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N'',4,4,14-PENTAMETHYL-, (3,5,20S)-
4-TERT-BUTYLCYCLOHEXYLAMINE, CIS
Cyclovirobuxin D
SPIRO[2.5]OCTANE